Targeting BET bromodomains for cancer treatment

Epigenomics

Volumn 7, Issue 3, 2015, Pages 487-501

  Jung, Marie ^a,b   Gelato, Kathy A ^a   Fernández Montalván, Amaury ^a   Siegel, Stephan ^a   Haendler, Bernard ^a  

^a BAYER PHARMA AG   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

BET inhibitor; BRD4; bromodomain; c Myc; chromatin; transcription control

Indexed keywords

ANTINEOPLASTIC AGENT; AZEPINE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BRD4 PROTEIN; BROMODOMAIN INHIBITOR; DIAZEPAM; HISTONE; I BET 726; ISOXAZOLE DERIVATIVE; NAPHTHYRIDINE DERIVATIVE; NONHISTONE PROTEIN; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN; PYRIDAZINONE DERIVATIVE; PYRIDONE DERIVATIVE; QUINAZOLINONE DERIVATIVE; RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; BRD4 PROTEIN, HUMAN; NUCLEAR PROTEIN;

BIOLOGICAL FUNCTIONS; CANCER THERAPY; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL TRIAL (TOPIC); GENE EXPRESSION PROFILING; HUMAN; LEUKEMIA; LYMPHOMA; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SOLID TUMOR; TRANSCRIPTION ELONGATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; HEMATOLOGIC NEOPLASMS; METABOLISM; MOUSE; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; HEMATOLOGIC NEOPLASMS; HUMANS; MICE; NUCLEAR PROTEINS; PROTEIN STRUCTURE, TERTIARY; TRANSCRIPTION FACTORS;

EID: 84931306037     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.14.91     Document Type: Review

References (121)

1. Roy DM, Walsh LA, Chan TA. Driver mutations of cancer epigenomes. Protein Cell 5(4), 265-296 (2014).
2. Loven J, Hoke HA, Lin CY et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153(2), 320-334 (2013).
3. Kurdistani SK. Chromatin: a capacitor of acetate for integrated regulation of gene expression and cell physiology. Curr. Opin. Genet. Dev. 26C, 53-58 (2014).
4. Marmorstein R, Zhou MM. Writers and readers of histone acetylation: structure, mechanism, and inhibition. Cold Spring Harb. Perspect. Biol. 6(7), a018762 (2014).
5. Slingerland M, Guchelaar HJ, Gelderblom H. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. Anticancer Drugs 25(2), 140-149 (2014).
6. West AC, Smyth MJ, Johnstone RW. The anticancer effects of HDAC inhibitors require the immune system. Oncoimmunology 3(1), e27414 (2014).
7. Gallenkamp D, Gelato KA, Haendler B, Weinmann H. Bromodomains and their pharmacological inhibitors. ChemMedChem 9, 438-464 (2014).
8. Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat. Rev. Drug Discov. 13(5), 337-356 (2014).
9. Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol. Cell 54(5), 728-736 (2014).
10. Filippakopoulos P, Qi J, Picaud S et al. Selective inhibition of BET bromodomains. Nature 468(7327), 1067-1073 (2010).
11. Nicodeme E, Jeffrey KL, Schaefer U et al. Suppression of inflammation by a synthetic histone mimic. Nature 468(7327), 1119-1123 (2010).
12. Anders L, Guenther MG, Qi J et al. Genome-wide localization of small molecules. Nat. Biotechnol. 32(1), 92-96 (2014).
13. Houzelstein D, Bullock SL, Lynch DE, Grigorieva EF, Wilson VA, Beddington RS. Growth and early postimplantation defects in mice deficient for the bromodomain-containing protein Brd4. Mol. Cell. Biol. 22(11), 3794-3802 (2002).
14. Lamonica JM, Deng W, Kadauke S et al. Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes. Proc. Natl Acad. Sci. USA 108(22), E159-E168 (2011).
15. Wang F, Deeney JT, Denis GV. Brd2 gene disruption causes "metabolically healthy" obesity: epigenetic and chromatinbased mechanisms that uncouple obesity from Type 2 diabetes. Vitam. Horm. 91, 49-75 (2013).
16. Berkovits BD, Wolgemuth DJ. The role of the double bromodomain-containing BET genes during mammalian spermatogenesis. Curr. Top. Dev. Biol. 102, 293-326 (2013).
17. Baud MG, Lin-Shiao E, Cardote T et al. Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes. Science 346(6209), 638-641 (2014).
18. Vollmuth F, Blankenfeldt W, Geyer M. Structures of the dual bromodomains of the P-TEFb-activating protein Brd4 at atomic resolution. J. Biol. Chem. 284(52), 36547-36556 (2009).
19. Filippakopoulos P, Picaud S, Mangos M et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149(1), 214-231 (2012).
20. Jung M, Philpott M, Muller S et al. Affinity Map of BRD4 Interactions with the histone H4 tail and the small molecule inhibitor JQ1. J. Biol. Chem. 289(13), 9304-9319 (2014).
21. Zhang W, Prakash C, Sum C et al. Bromodomaincontaining protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J. Biol. Chem. 287(51), 43137-43155 (2012).
22. Nishiyama A, Dey A, Miyazaki J, Ozato K. Brd4 is required for recovery from antimicrotubule drug-induced mitotic arrest: preservation of acetylated chromatin. Mol. Biol. Cell 17(2), 814-823 (2006).
23. Chen R, Yik JH, Lew QJ, Chao SH. Brd4 and HEXIM1: multiple roles in P-TEFb regulation and cancer. Biomed. Res. Int. 2014, 232870 (2014).
24. Itzen F, Greifenberg AK, Bosken CA, Geyer M. Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation. Nucleic Acids Res. 42(12), 7577-7590 (2014).
25. Bisgrove DA, Mahmoudi T, Henklein P, Verdin E. Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. Proc. Natl Acad. Sci. USA 104(34), 13690-13695 (2007).
26. Schroder S, Cho S, Zeng L et al. Two-pronged binding with bromodomain-containing protein 4 liberates positive transcription elongation factor b from inactive ribonucleoprotein complexes. J. Biol. Chem. 287(2), 1090-1099 (2012).
27. Liu W, Ma Q, Wong K et al. Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release. Cell 155(7), 1581-1595 (2013).
28. Devaiah BN, Singer DS. Two faces of brd4: mitotic bookmark and transcriptional lynchpin. Transcription 4(1), 13-17 (2013).
29. Zou Z, Huang B, Wu X et al. Brd4 maintains constitutively active NF-kappaB in cancer cells by binding to acetylated RelA. Oncogene 33(18), 2395-2404 (2014).
30. Asangani IA, Dommeti VL, Wang X et al. Therapeutic targeting of BET bromodomain proteins in castrationresistant prostate cancer. Nature 510(7504), 278-282 (2014).
31. Feng Q, Zhang Z, Shea MJ et al. An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 24(7), 809-819 (2014).
32. Nagarajan S, Hossan T, Alawi M et al. Bromodomain protein BRD4 Is required for estrogen receptor-dependent enhancer activation and gene transcription. Cell Rep. 8(2), 460-469 (2014).
33. Shi J, Wang Y, Zeng L et al. Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. Cancer Cell 25(2), 210-225 (2014).
34. Wu SY, Lee AY, Lai HT, Zhang H, Chiang CM. Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. Mol. Cell 49(5), 843-857 (2013).
35. Ray S, Zhao Y, Jamaluddin M, Edeh CB, Lee C, Brasier AR. Inducible STAT3 NH2 terminal mono-ubiquitination promotes BRD4 complex formation to regulate apoptosis. Cell Signal. 26(7), 1445-1455 (2014).
36. Gamsjaeger R, Webb SR, Lamonica JM, Billin A, Blobel GA, Mackay JP. Structural basis and specificity of acetylated transcription factor GATA1 recognition by BET family bromodomain protein Brd3. Mol. Cell. Biol. 31(13), 2632-2640 (2011).
37. Rahman S, Sowa ME, Ottinger M et al. The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. Mol. Cell. Biol. 31(13), 2641-2652 (2011).
38. Bonora G, Plath K, Denholtz M. A mechanistic link between gene regulation and genome architecture in mammalian development. Curr. Opin. Genet. Dev. 27C, 92-101 (2014).
39. Hu X, Lu X, Liu R et al. Histone crosstalk connects protein phosphatase 1alpha (PP1alpha) and histone deacetylase (HDAC) pathways to regulate the functional transition of bromodomain-containing 4 (Brd4) for inducible gene expression. J. Biol. Chem. 289(33), 23154-23167 (2014).
40. Kanno T, Kanno Y, Siegel RM, Jang MK, Lenardo MJ, Ozato K. Selective recognition of acetylated histones by bromodomain proteins visualized in living cells. Mol. Cell 13(1), 33-43 (2004).
41. Wang R, Li Q, Helfer CM, Jiao J, You J. The bromodomain protein Brd4 associated with acetylated chromatin is important for maintenance of higher-order chromatin structure. J. Biol. Chem. 287(14), 10738-10752 (2012).
42. Garcia-Gutierrez P, Mundi M, Garcia-Dominguez M. Association of bromodomain BET proteins to the chromatin requires dimerization through the conserved motif B. J. Cell Sci. 125(Pt 15), 3671-3680 (2012).
43. Picaud S, Wells C, Felletar I et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc. Natl Acad. Sci. USA 110(49), 19754-19759 (2013).
44. Delmore JE, Issa GC, Lemieux ME et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146(6), 904-917 (2011). myeloma models.
45. Fowler T, Ghatak P, Price DH et al. Regulation of MYC expression and differential JQ1 sensitivity in cancer cells. PLoS ONE 9(1), e87003 (2014).
46. Lockwood WW, Zejnullahu K, Bradner JE, Varmus H. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc. Natl Acad. Sci. USA 109(47), 19408-19413 (2012).
47. Chapuy B, Mckeown MR, Lin CY et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 24(6), 777-790 (2013).
48. You J, Li Q, Wu C, Kim J, Ottinger M, Howley PM. Regulation of aurora B expression by the bromodomain protein Brd4. Mol. Cell. Biol. 29(18), 5094-5103 (2009).
49. Mochizuki K, Nishiyama A, Jang MK et al. The bromodomain protein Brd4 stimulates G1 gene transcription and promotes progression to S phase. J. Biol. Chem. 283(14), 9040-9048 (2008).
50. Yang Z, He N, Zhou Q. Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression. Mol. Cell. Biol. 28(3), 967-976 (2008).
51. Dawson MA, Gudgin EJ, Horton SJ et al. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia. Leukemia 28(2), 311-320 (2014).
52. Tang Y, Gholamin S, Schubert S et al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat. Med. 20(7), 732-740 (2014).
53. Bhadury J, Nilsson LM, Veppil Muralidharan S et al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc. Natl Acad. Sci. USA 111(26), E2721-E2730 (2014).
54. Hussong M, Borno ST, Kerick M et al. The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response. Cell Death Dis. 5, e1195 (2014).
55. Floyd SR, Pacold ME, Huang Q et al. The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature 498(7453), 246-250 (2013).
56. Gacias M, Gerona-Navarro G, Plotnikov AN et al. Selective chemical modulation of gene transcription favors oligodendrocyte lineage progression. Chem. Biol. 21(7), 841-854 (2014).
57. Zuber J, Shi J, Wang E et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478(7370), 524-528 (2011).
58. Mertz JA, Conery AR, Bryant BM et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl Acad. Sci. USA 108(40), 16669-16674 (2011).
59. Herrmann H, Blatt K, Shi J et al. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem-and progenitor cells in acute myeloid leukemia AML. Oncotarget 3(12), 1588-1599 (2012).
60. Dawson MA, Prinjha RK, Dittmann A et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478(7370), 529-533 (2011).
61. Da Costa D, Agathanggelou A, Perry T et al. BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia. Blood Cancer J 3, e126 (2013).
62. Chaidos A, Caputo V, Gouvedenou K et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood 123(5), 697-705 (2014).
63. Trabucco SE, Gerstein RM, Evens AM et al. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clin. Cancer Res. 21(1), 113-122 (2014).
64. Ceribelli M, Kelly PN, Shaffer AL et al. Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc. Natl Acad. Sci. USA 111(31), 11365-11370 (2014).
65. Emadali A, Rousseaux S, Bruder-Costa J et al. Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls rituximab response and tumour growth in aggressive lymphoid cancers. EMBO Mol. Med. 5(8), 1180-1195 (2013).
66. Moros A, Rodriguez V, Saborit-Villarroya I et al. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma. Leukemia 28(10), 2049-2059 (2014).
67. French CA. Pathogenesis of NUT midline carcinoma. Annu. Rev. Pathol. 7, 247-265 (2012).
68. Grayson AR, Walsh EM, Cameron MJ et al. MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma. Oncogene 33(13), 1736-1742 (2014).
69. Reynoird N, Schwartz BE, Delvecchio M et al. Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J. 29(17), 2943-2952 (2010).
70. Shimamura T, Chen Z, Soucheray M et al. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin. Cancer Res. 19(22), 6183-6192 (2013).
71. Wyce A, Degenhardt Y, Bai Y et al. Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. Oncotarget 4(12), 2419-2429 (2013).
72. Draker R, Ng MK, Sarcinella E, Ignatchenko V, Kislinger T, Cheung P. A combination of H2A.Z and H4 acetylation recruits Brd2 to chromatin during transcriptional activation. PLoS Genet. 8(11), e1003047 (2012).
73. Sahai V, Kumar K, Knab LM et al. BET bromodomain inhibitors block growth of pancreatic cancer cells in threedimensional collagen. Mol. Cancer Ther. 13(7), 1907-1917 (2014).
74. Segura MF, Fontanals-Cirera B, Gaziel-Sovran A et al. BRD4 sustains proliferation and represents a new target for epigenetic therapy in melanoma. Cancer Res. 73(20), 6264-6276 (2013).
75. Gallagher SJ, Mijatov B, Gunatilake D et al. The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells. J. Invest. Dermatol. 34(11), 2795-2805 (2014).
76. Gallagher SJ, Mijatov B, Gunatilake D et al. Control of NFkB activity in human melanoma by bromodomain and extraterminal protein inhibitor I-BET151. Pigment Cell Melanoma Res. 27(6), 1126-1137 (2014).
77. Cheng Z, Gong Y, Ma Y et al. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin. Cancer Res. 19(7), 1748-1759 (2013).
78. Pastori C, Daniel M, Penas C et al. BET bromodomain proteins are required for glioblastoma cell proliferation. Epigenetics 9(4), 611-20 (2014).
79. Puissant A, Frumm SM, Alexe G et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 3(3), 308-323 (2013).
80. Wyce A, Ganji G, Smitheman KN et al. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PLoS ONE 8(8), e72967 (2013).
81. Henssen A, Thor T, Odersky A et al. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget 4(11), 2080-2095 (2013).
82. Bandopadhayay P, Bergthold G, Nguyen B et al. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin. Cancer Res. 20(4), 912-925 (2014).
83. Smith SG, Sanchez R, Zhou MM. Privileged diazepine compounds and their emergence as bromodomain inhibitors. Chem. Biol. 21(5), 573-583 (2014).
84. Sanchez R, Meslamani J, Zhou MM. The bromodomain: from epigenome reader to druggable target. Biochim. Biophys. Acta 1839(8), 676-685 (2014).
85. Zhang G, Plotnikov AN, Rusinova E et al. Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains. J. Med. Chem. 56(22), 9251-9264 (2013).
86. Mclure KG, Gesner EM, Tsujikawa L et al. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. PLoS ONE 8(12), e83190 (2013).
87. Chung CW, Witherington J. Progress in the discovery of small-molecule inhibitors of bromodomain-histone interactions. J. Biomol. Screen. 16(10), 1170-1185 (2011).
88. Seal J, Lamotte Y, Donche F et al. Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A). Bioorg. Med. Chem. Lett. 22(8), 2968-2972 (2012).
89. Chung CW, Coste H, White JH et al. Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J. Med. Chem. 54(11), 3827-3838 (2011).
90. Mirguet O, Lamotte Y, Donche F et al. From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151. Bioorg. Med. Chem. Lett. 22(8), 2963-2967 (2012).
91. Gehling VS, Hewitt MC, Vaswani RG et al. Discovery, design, and optimization of isoxazole azepine BET inhibitors. ACS Med. Chem. Lett. 4(9), 835-840 (2013).
92. Fish PV, Filippakopoulos P, Bish G et al. Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. J. Med. Chem. 55(22), 9831-9837 (2012).
93. Vidler LR, Filippakopoulos P, Fedorov O et al. Discovery of novel small-molecule inhibitors of BRD4 using structurebased virtual screening. J. Med. Chem. 56(20), 8073-8088 (2013).
94. Muvva C, Singam ER, Raman SS, Subramanian V. Structure-based virtual screening of novel, high-affinity BRD4 inhibitors. Mol. Biosyst. 10(9), 2384-2397 (2014).
95. Lucas X, Wohlwend D, Hugle M et al. 4-acyl pyrroles: mimicking acetylated lysines in histone code reading. Angew. Chem. Int. Ed. Engl. 52(52), 14055-14059 (2013).
96. Lefker BA, Shin J, Williams C et al. Design and chemoproteomic functional characterization of a chemical probe targeted to bromodomains of BET family proteins. MedChemComm.5 1871-1879 (2014).
97. Philpott M, Yang J, Tumber T et al. Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. Mol. Biosyst. 7(10), 2899-2908 (2011).
98. Picaud S, Da Costa D, Thanasopoulou A et al. PFI-1-A highly selective protein interaction inhibitor targeting BET bromodomains. Cancer Res. 73(11), 3336-3346 (2013).
99. Ciceri P, Muller S, O'mahony A et al. Dual kinasebromodomain inhibitors for rationally designed polypharmacology. Nat. Chem. Biol. 10(4), 305-312 (2014).
100. Schulze J, Moosmayer D, Weiske J et al. Cell-based protein stabilization assays for the detection of interactions between small-molecule inhibitors and BRD4. J. Biomol. Screen. 20(2), 180-189 (2014).
101. Zhang G, Liu R, Zhong Y et al. Down-regulation of NFkappaB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J. Biol. Chem. 287(34), 28840-28851 (2012).
102. Liu R, Zhong Y, Li X et al. Role of transcription factor acetylation in diabetic kidney disease. Diabetes 63(7), 2440-2453 (2014).
103. Mirguet O, Gosmini R, Toum J et al. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. J. Med. Chem. 56(19), 7501-7515 (2013).
104. Garnier JM, Sharp PP, Burns CJ. BET bromodomain inhibitors: a patent review. Expert Opin. Ther. Pat. 24(2), 185-199 (2014).
105. Schmees N, Haendler B, Lejeune P et al. New benzazepine BET-inhibitors with improved oral bioavailability. Presented at: 105th Annual Meeting of the American Association for Cancer Research; San Diego, CA, USA 5-9 April 2014.
106. Filippakopoulos P, Picaud S, Fedorov O et al. Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family. Bioorg. Med. Chem. 20(6), 1878-1886 (2012).
107. Hewings DS, Wang M, Philpott M et al. 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J. Med. Chem. 54(19), 6761-6770 (2011).
108. Bamborough P, Brown MJ, Christopher JA, Chung CW, Mellor GW. Selectivity of kinase inhibitor fragments. J. Med. Chem. 54(14), 5131-5143 (2011).
109. Hay D, Fedorov O, Filippakopoulos P et al. The design and synthesis of 5-and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains. MedChemComm 4(1), 140-144 (2013).
110. Shahbazi J, Scarlett CJ, Norris MD et al. Histone deacetylase and N-Myc reduce p53 protein phosphorylation at serine by repressing gene transcription of tumor protein 53-induced nuclear protein 1. Oncotarget 5(12), 4257-4268 (2014).
111. Gosmini R, Nguyen VL, Toum J et al. The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor. J. Med. Chem. 57(19), 8111-8131 (2014).
112. Arnold LD, Foreman KW, Werner DS: WO2013033268 A2(PCT/US2012/052941) (2013).
113. Mirguet O, Lamotte Y, Chung CW et al. Naphthyridines as novel BET family bromodomain inhibitors. ChemMedChem 9(3), 580-589 (2014).
114. Chung CW, Dean AW, Woolven JM, Bamborough P. Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery. J. Med. Chem. 55(2), 576-586 (2012).
115. Zhao L, Cao D, Chen T et al. Fragment-based drug discovery of 2-thiazolidinones as inhibitors of the histone reader BRD4 bromodomain. J. Med. Chem. 56(10), 3833-3851 (2013).
116. Ito T, Umehara T, Sasaki K et al. Real-time imaging of histone H4K12-specific acetylation determines the modes of action of histone deacetylase and bromodomain inhibitors. Chem. Biol. 18(4), 495-507 (2011).
117. Fedorov O, Lingard H, Wells C et al. [1,2,4]triazolo[4,3-a] phthalazines: inhibitors of diverse bromodomains. J. Med. Chem. 57(2), 462-476 (2014).
118. Dittmann A, Werner T, Chung CW et al. The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains. ACS Chem. Biol. 9(2), 495-502 (2014).
119. Martin MP, Olesen SH, Georg GI, Schonbrunn E. Cyclindependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. ACS Chem. Biol. 8(11), 2360-2365 (2013).
120. Ember SW, Zhu JY, Olesen SH et al. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors. ACS Chem. Biol. 9(5), 1160-1171 (2014).
121. ClinicalTrials database. http://clinicaltrials.gov/